Paul Wallace

Paul manages the Board and guides the Executive Team on partnering and business development. He is Chief Business Officer at Mission Therapeutics. Paul has been involved in several trade sales and has executed over $4.5B worth of outlicensing partnerships including the hepatitis C protease inhibitor, Olysio.